Semaglutide, tirzepatide and retatrutide are often grouped together, but they activate different combinations of metabolic receptors and have different evidence bases.
Research-use notice: This article summarizes receptor pharmacology and published studies for educational purposes. It is not medical advice, a comparison of personal treatment options, or an administration guide. Clinical trial products and unverified research materials are not interchangeable.
Semaglutide, tirzepatide and retatrutide are often discussed as successive generations of “GLP-1” research. That shorthand is incomplete. Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates the GIP and GLP-1 receptors. Retatrutide is designed to activate GIP, GLP-1 and glucagon receptors. The additional targets change the experimental questions, but they do not make the compounds directly comparable without careful controls.
This review separates receptor design from clinical evidence. That distinction matters because results from different trials, populations and pharmaceutical formulations cannot be ranked as if they came from one head-to-head experiment.
At-a-glance comparison
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor design | GLP-1 receptor agonist | GIP and GLP-1 receptor agonist | GIP, GLP-1 and glucagon receptor agonist |
| Common research description | Single-receptor incretin analogue | Dual agonist | Triple agonist |
| Landmark obesity evidence | STEP program, including a phase 3 randomized trial | SURMOUNT program, including phase 3 randomized trials | Phase 2 publication plus ongoing/completed phase 3 program reporting |
| Canadian regulatory context, August 2026 | Health Canada-authorized semaglutide drug products exist | Health Canada-authorized tirzepatide drug products exist | Retatrutide remains investigational and is not an authorized drug product |
| Main comparison challenge | Isolating GLP-1R effects from formulation and exposure | Separating GIPR contribution from GLP-1R activity | Separating glucagon-receptor contribution from the two incretin pathways |
| Research-material caution | A research vial is not equivalent to an authorized drug product | A research vial is not equivalent to an authorized drug product | Trial results do not validate material sold outside the sponsor’s development program |
Semaglutide: the single-receptor reference point
Semaglutide is an analogue engineered for prolonged GLP-1 receptor activation. GLP-1 receptor signaling is associated with glucose-dependent insulin secretion, suppression of glucagon under relevant glucose conditions, delayed gastric emptying and central appetite-related pathways. The relative contribution of each pathway depends on the model, exposure and endpoint.
The STEP 1 randomized trial enrolled adults with overweight or obesity who did not have diabetes and compared a regulated semaglutide formulation plus lifestyle intervention with placebo plus lifestyle intervention over 68 weeks. The study reported a mean body-weight change of −14.9% in the semaglutide group and −2.4% in the placebo group. Gastrointestinal events were common, and discontinuation due to gastrointestinal events was more frequent with semaglutide than placebo.
Those results are frequently quoted, but their scope must be preserved. They describe one clinical formulation, protocol and population. They do not establish the composition, purity, sterility, safety or performance of a separately sourced research material.
Tirzepatide: adding GIP-receptor activity
Tirzepatide is a single peptide designed to activate both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and GLP-1 receptor (GLP-1R). The dual-agonist concept asks whether coordinated signaling through the two incretin receptors can produce a biological profile that differs from GLP-1R activation alone.
The SURMOUNT-1 phase 3 trial studied adults with obesity or overweight and at least one related condition, excluding diabetes. At 72 weeks, mean percentage changes in body weight ranged from −15.0% to −20.9% across the studied tirzepatide groups, compared with −3.1% for placebo. Gastrointestinal events were the most common adverse events and occurred mainly during dose escalation.
That trial was not a direct comparison with STEP 1. Differences in enrolment, duration, estimands, background intervention and other protocol details prevent a clean cross-trial ranking. A later head-to-head trial of regulated medicines can answer a different clinical question, but it still does not validate research-grade products or support extrapolation to laboratory materials with unknown comparability.
Retatrutide: adding glucagon-receptor activity
Retatrutide, also known by the development code LY3437943, is designed to activate GIPR, GLP-1R and the glucagon receptor (GCGR). Preclinical work described triple-receptor activity and investigated how GCGR activation could affect energy expenditure alongside the incretin pathways.
A phase 2 randomized trial in adults with obesity or overweight reported dose-dependent changes in body weight over 24 and 48 weeks. The study’s most common adverse events were gastrointestinal, and heart-rate changes were also among the measured safety observations. These findings supported a larger phase 3 development program.
As of August 28, 2026, retatrutide remains an investigational molecule rather than an authorized drug product. Regulatory status must be checked again immediately before publication because it can change. Trial data concern material manufactured and controlled for the sponsor’s clinical program; they should never be treated as evidence about an unrelated catalogue product.
Why “single, dual and triple” is not a potency ranking
Counting receptor targets is useful for classification, not for declaring one molecule universally “stronger.” Several variables determine the observed profile:
Receptor balance
A multi-receptor peptide may have different relative activity at each target. Three targets do not necessarily contribute equally, and apparent activity can vary by assay system.
Intrinsic efficacy and signaling bias
Two ligands at the same receptor can produce different maximal responses or favour different downstream signaling patterns. A receptor list cannot capture that behaviour.
Exposure and molecular design
Half-life extension, protein binding, absorption and clearance affect the time course of receptor engagement. Equal nominal concentrations do not guarantee equal free exposure.
Tissue and species expression
Receptor abundance differs among cell lines, tissues and species. A model rich in one receptor may exaggerate that pathway’s contribution compared with another model.
Endpoint selection
Insulin secretion, glucagon signaling, food-intake behaviour, energy expenditure, gastric motility and body composition are distinct endpoints. A study optimized for one should not be generalized to all the others.
How to design a defensible laboratory comparison
1. Define the question before selecting the model
A receptor-potency experiment, a signaling-pathway experiment and an in vivo metabolic experiment need different designs. “Which compound is best?” is not a testable laboratory endpoint.
2. Confirm material identity
Document the sequence, terminal modifications, theoretical mass, lot number and source. Use mass spectrometry for identity and chromatography for purity. A vendor name or label is not an analytical result.
3. Use receptor-selective systems
For mechanistic work, single-receptor expression systems can help estimate activity at GLP-1R, GIPR and GCGR separately. Multi-receptor systems may be added later to test interaction effects.
4. Normalize exposure appropriately
Compare molar concentration rather than vial mass, and consider protein binding and stability in the selected matrix. Document solvent, pH, carrier proteins, temperature and sample history.
5. Predefine controls and endpoints
Include vehicle and receptor-appropriate reference ligands. Use validated readouts, prespecified time points and an analysis plan that distinguishes receptor activation from downstream physiological changes.
6. Avoid unsupported cross-trial conclusions
Clinical trials can contextualize the development programs, but they are not substitutes for head-to-head laboratory controls. When reporting trial results, include population, duration, comparator and formulation.
Evidence hierarchy for this comparison
| Evidence type | What it can support | What it cannot support |
|---|---|---|
| Receptor assays | Relative activity in a defined system | Whole-organism effectiveness or safety |
| Animal studies | Integrated responses in a specified species and model | Automatic prediction of human outcomes |
| Randomized clinical trials | Outcomes for the tested product, protocol and population | Quality or equivalence of outside research materials |
| Regulatory authorization | Benefit-risk and quality findings for a specific drug product and indication | Authorization of every product containing the same named peptide |
| Supplier COA | Lot-specific analytical evidence within the methods used | Clinical safety, efficacy or regulatory approval |
Frequently asked questions
Is retatrutide simply a stronger version of tirzepatide?
No. Retatrutide has a third receptor target, GCGR, and a different molecular profile. “Stronger” is not meaningful without specifying receptor, assay, exposure, endpoint and comparator.
Can results from STEP 1, SURMOUNT-1 and the retatrutide phase 2 trial be directly ranked?
Not cleanly. They used different populations, durations, protocols and development products. Cross-trial comparisons are descriptive and vulnerable to confounding.
Are semaglutide and tirzepatide approved in Canada?
Health Canada has authorized specific semaglutide and tirzepatide drug products for defined indications. That authorization applies to the named, regulated products—not to research vials or independently manufactured materials.
Is retatrutide approved in Canada?
As of August 28, 2026, no. It remains investigational. This status should be rechecked before publication and at every scheduled content review.
Does a high HPLC purity result make a research material equivalent to a clinical product?
No. HPLC area percentage is one analytical measure. Equivalence would require much broader evidence, including identity, impurities, content, formulation, manufacturing controls, sterility where applicable, stability and regulatory review.
Bottom line
Semaglutide, tirzepatide and retatrutide represent different receptor strategies: GLP-1 alone, dual GIP/GLP-1 activation and triple GIP/GLP-1/glucagon activation. The extra targets expand the research hypothesis; they do not create a simple potency ladder. Reliable comparisons require receptor-specific assays, verified material identity, exposure-aware design and careful separation of clinical evidence from research-product claims.
For related background, see Tirzepatide vs Retatrutide and Retatrutide Research Review 2026. For analytical controls, use the Peptide COA Guide.
References
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002. doi:10.1056/NEJMoa2032183. PMID: 33567185.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–216. doi:10.1056/NEJMoa2206038. PMID: 35658024.
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity—A phase 2 trial. N Engl J Med. 2023;389:514–526. doi:10.1056/NEJMoa2301972. PMID: 37366315.
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247.e9. doi:10.1016/j.cmet.2022.07.013. PMID: 35985340.
- Health Canada. Regulatory Decision Summary for Wegovy.
- Health Canada. Drug and Health Products Portal: Zepbound.
- Eli Lilly and Company. What to know about retatrutide. Status should be rechecked before publication.